Castleark Management LLC Makes New Investment in Ralliant Corporation $RAL

Castleark Management LLC bought a new stake in shares of Ralliant Corporation (NYSE:RAL) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 128,740 shares of the company’s stock, valued at approximately $9,479,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in RAL. BlackRock Inc. bought a new position in Ralliant in the 2nd quarter worth $1,039,481,000. Irenic Capital Management LP boosted its holdings in Ralliant by 424.1% during the first quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock valued at $72,376,000 after acquiring an additional 1,408,176 shares during the period. Rokos Capital Management LLP bought a new stake in Ralliant during the first quarter valued at about $42,022,000. Flossbach Von Storch SE acquired a new stake in shares of Ralliant in the second quarter valued at about $222,460,000. Finally, California State Teachers Retirement System increased its stake in shares of Ralliant by 23.1% in the first quarter. California State Teachers Retirement System now owns 130,822 shares of the company’s stock worth $5,441,000 after purchasing an additional 24,591 shares during the period.

Insider Activity at Ralliant

In related news, CEO Tamara S. Newcombe sold 12,936 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer owned 251,967 shares of the company’s stock, valued at $18,088,710.93. The trade was a 4.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the sale, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.42% of the company’s stock.

Ralliant Trading Down 1.7%

Shares of RAL stock opened at $61.87 on Wednesday. The firm has a fifty day moving average of $68.69 and a 200-day moving average of $56.04. The stock has a market cap of $6.85 billion, a price-to-earnings ratio of -5.70, a P/E/G ratio of 2.34 and a beta of 1.60. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52.

Ralliant (NYSE:RAL) last issued its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities research analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s dividend payout ratio is currently -1.84%.

Wall Street Analysts Forecast Growth

RAL has been the subject of several recent analyst reports. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. Truist Financial restated a “buy” rating and issued a $82.00 price objective (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Citigroup upped their target price on shares of Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.